JP2024534427A5 - - Google Patents

Info

Publication number
JP2024534427A5
JP2024534427A5 JP2024516849A JP2024516849A JP2024534427A5 JP 2024534427 A5 JP2024534427 A5 JP 2024534427A5 JP 2024516849 A JP2024516849 A JP 2024516849A JP 2024516849 A JP2024516849 A JP 2024516849A JP 2024534427 A5 JP2024534427 A5 JP 2024534427A5
Authority
JP
Japan
Prior art keywords
milbexian
use according
pharmaceutically acceptable
acceptable salt
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534427A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/043797 external-priority patent/WO2023043999A1/en
Publication of JP2024534427A publication Critical patent/JP2024534427A/ja
Publication of JP2024534427A5 publication Critical patent/JP2024534427A5/ja
Pending legal-status Critical Current

Links

JP2024516849A 2021-09-17 2022-09-16 血栓塞栓性障害を予防かつ治療するためのミルベキシアン Pending JP2024534427A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US63/245,522 2021-09-17
US202163278582P 2021-11-12 2021-11-12
US63/278,582 2021-11-12
PCT/US2022/043797 WO2023043999A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Publications (2)

Publication Number Publication Date
JP2024534427A JP2024534427A (ja) 2024-09-20
JP2024534427A5 true JP2024534427A5 (cg-RX-API-DMAC7.html) 2025-09-25

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516849A Pending JP2024534427A (ja) 2021-09-17 2022-09-16 血栓塞栓性障害を予防かつ治療するためのミルベキシアン

Country Status (11)

Country Link
US (1) US20250099466A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401736A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024534427A (cg-RX-API-DMAC7.html)
KR (1) KR20240060820A (cg-RX-API-DMAC7.html)
AU (1) AU2022345862A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232633A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000776A1 (cg-RX-API-DMAC7.html)
IL (1) IL310894A (cg-RX-API-DMAC7.html)
MX (1) MX2024002857A (cg-RX-API-DMAC7.html)
TW (1) TW202327607A (cg-RX-API-DMAC7.html)
WO (1) WO2023043999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565231A1 (en) * 2022-08-01 2025-06-11 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke
CN121001727A (zh) * 2023-04-19 2025-11-21 百时美施贵宝公司 米尔维仙(milvexian)于治疗及预防患有心血管或脑血管疾病的患者的血栓病况的用途
CN121443289A (zh) * 2023-04-19 2026-01-30 百时美施贵宝公司 米尔维仙在治疗或预防患有急性冠状动脉综合征的患者的不良脑血管事件或不良心血管事件中的用途
CN121398811A (zh) * 2023-04-19 2026-01-23 百时美施贵宝公司 米尔维仙于治疗及预防患有心房颤动的患者的血栓病况的用途
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2026115567A1 (en) * 2024-11-26 2026-06-04 Dr. Reddy’S Laboratories Limited Sustained release formulations of milvexian

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR20210151183A (ko) 2019-04-11 2021-12-13 브리스톨-마이어스 스큅 컴퍼니 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능

Similar Documents

Publication Publication Date Title
IL310894A (en) Milovacian for the prevention and treatment of thromboembolic disorders
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP2017510607A5 (cg-RX-API-DMAC7.html)
CN107519159A (zh) 复方组合物
JP2023535744A5 (cg-RX-API-DMAC7.html)
JP2023552700A5 (cg-RX-API-DMAC7.html)
JP2022550919A5 (cg-RX-API-DMAC7.html)
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
JP2023526754A5 (cg-RX-API-DMAC7.html)
JP2021532171A5 (cg-RX-API-DMAC7.html)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2016505050A5 (cg-RX-API-DMAC7.html)
MX2022012693A (es) Composicion que comprende metilfolato.
JP2024540439A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2024520690A5 (cg-RX-API-DMAC7.html)
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
US9545419B1 (en) Method and compositions for treating chronic inflammatory disorders
JP2024527175A5 (cg-RX-API-DMAC7.html)
US20110117070A1 (en) Compositions and methods for treating headache
CN108472375A (zh) 中重度流感的治疗方法
JP2022504435A5 (cg-RX-API-DMAC7.html)
JP2017511307A5 (cg-RX-API-DMAC7.html)
IL319025A (en) Methods for treating or preventing endometriosis
JP2021521227A5 (cg-RX-API-DMAC7.html)